Skip to content
Open access

Adaptive Trial Designs for Assessing Predictiveness of a Biomarker in Early Phase Drug Development

Sep 2026 · Statistics in Medicine · Vol 45 · 0 citations · 32 references
Medicine

TL;DR

An adaptive design is proposed to improve power for detecting a predictive effect when sample sizes are small, and addresses key methodological challenges, including interim decision rules, determining the magnitude and allocation of post‐interim sample size increases, controlling the Type I error rate, and achieving meaningful gains in statistical power at the final analysis.

Abstract

Biomarker identification plays a crucial role in precision medicine, where treatments are tailored to patients' intrinsic factors. Predictive biomarkers can be used to identify patients who are more likely to benefit from a treatment. However, identifying and validating such biomarkers pose substantial statistical and practical challenges, especially in the small sample setting. Several methods have been proposed for assessing whether a biomarker has a predictive effect, including the Average Kolmogorov‐Smirnov Approach (AKSA), which has been shown to have improved operating characteristics for inference compared to alternative approaches. Yet power remains limited when sample sizes are small and unbalanced across treatment arms. Power can be improved through adaptive enrichment of the sample size, especially when treatment arms are small and unbalanced. We propose an adaptive design to improve power for detecting a predictive effect when sample sizes are small. Existing adaptive biomarker designs largely focus on enrichment of the trial, for example, adjusting enrolment criteria based on an assessment of the treatment‐biomarker interaction at interim, or refining the biomarker threshold used to segregate the population into biomarker positive or negative (i.e., those patients more or less likely to respond to the treatment). Few designs explicitly address the task of formally declaring a predictive effect of a biomarker using an interim analysis. The interim analysis framework enables a more reliable assessment of a biomarker's predictive effect by introducing a pre‐planned evaluation at the originally intended sample size of a study which may otherwise be underpowered due to the limited number of patients. Based on the interim results, the trial may (i) already have sufficient evidence to declare a biomarker as predictive, (ii) be terminated early due to a clear lack of evidence for a predictive effect, or (iii) enter an “expansion phase”, where additional cohort of patients are recruited to improve the power for final analysis. The proposed framework addresses key methodological challenges, including interim decision rules, determining the magnitude and allocation of post‐interim sample size increases, controlling the Type I error rate, and achieving meaningful gains in statistical power at the final analysis. The impact of an unknown biomarker distribution is also considered. These challenges are explored through simulation studies, where properties of the interim and final analyses are presented under various design configurations (where the decision bounds and size of the expansion are altered) and scenarios, in which the true predictive and prognostic effects of the biomarker are varied. Evaluated metrics include statistical power, Type I error control, and interim decision characteristics. The results inform the design of trials incorporating interim analyses to assess the predictive effect of a biomarker, enabling statistically efficient and well‐calibrated decision‐making.

Read PDF

Similar papers

Open access Sep 2026

Applying the Promising Zone Method to Biomarker‐Based Adaptive Designs: A Word of Caution

It is shown that the promising zone method can produce Type I error inflation when embedded in biomarker‐based adaptive designs, with the magnitude of inflation depending on the underlying true treatment effect in the biomarker‐positive subgroup and specific design parameters such as the biomarker subgroup prevalence,...

Jing-Zhao Wang, Ruo-Bing Li, Jun Zhao et al. · 0 citations
Conference Open access Sep 2026

A Bayesian Single-Index Model with fixed intercept for multiple biomarkers subset effects in clinical trials

Predictive biomarkers like protein expressions have the potential of becoming the aid that predict treatment benefits for individual patients. Clinical trial data can be used in secondary analysis to determine the subset of patients who are the beneficiaries of a treatment regimen and the subset of patients who are not...

Braydon Hunter, Wen-Yu Jiang, Zong-Jun-Zong-Jun Liu · 0 citations
Open access Sep 2026

Bayesian Shrinkage Versus Frequentist Variable Selection in Small-Sample Translational Research: A Monte Carlo Simulation Study Grounded in Regenerative Medicine Biomarker Discovery

Introduction. Observational studies in regenerative medicine represent a promising frontier for the discovery of predictive biomarkers of therapeutic response, yet are structurally constrained by small sample sizes. This low-sample-size regime exposes variable selection methods to a high risk of overfitting and false d...

M. F. Di Tolla, Domenico Iervolino, Vittorio Scisciola et al. · 0 citations
Open access Oct 2026

A multivariate Bayesian biomarker screening algorithm that incorporates clinical covariates.

Advanced hepatocellular carcinoma (HCC) has limited treatment options and poor survival. Early detection of HCC improves survival, but current ultrasound screening is inconsistent and poorly adhered to. Biomarker-based blood tests offer a more accurate, accessible, and reliable alternative. Recent developments in metho...

Maria Veronica Vinattieri, F. Panero, Q. Jin et al. · 0 citations
Preprint Sep 2026

Multi-Objective Composite Longitudinal Biomarker Scores for Improved Cancer Risk Assessment

Improved Parametric Empirical Bayes (iPEB), which accounts for the intervals between serial measurements, adjusts for covariates, and performs feature selection and optimized biomarker combination, improved lung cancer risk assessment in independent PLCO data, supporting objective-driven optimization of longitudinal bi...

Bitan Sarkar, Ana M. Kenney, James P. Long et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.